Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases | Zendy

Carlos G. Grijalva | Zendy; Lang Chen | Zendy; Elizabeth Delzell | Zendy; John W. Baddley | Zendy; Timothy Beukelman | Zendy; Kevin Winthrop | Zendy; Marie R. Griffin | Zendy; Lisa J. Herrinton | Zendy; Liyan Liu | Zendy; Rita OuelletHellstrom | Zendy; Nivedita M. Patkar | Zendy; Daniel H. Solomon | Zendy; James D. Lewis | Zendy; Fenglong Xie | Zendy; Kenneth G. Saag | Zendy; Jeffrey R. Curtis | Zendy

Open Access

Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases

Author(s) -

Carlos G. Grijalva,

Lang Chen,

Elizabeth Delzell,

John W. Baddley,

Timothy Beukelman,

Kevin Winthrop,

Marie R. Griffin,

Lisa J. Herrinton,

Liyan Liu,

Rita OuelletHellstrom,

Nivedita M. Patkar,

Daniel H. Solomon,

James D. Lewis,

Fenglong Xie,

Kenneth G. Saag,

Jeffrey R. Curtis

Publication year - 2011

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2011.1692

Subject(s) - medicine , psoriasis , psoriatic arthritis , rheumatoid arthritis , etanercept , medicaid , hazard ratio , adalimumab , inflammatory bowel disease , ankylosing spondylitis , tumor necrosis factor alpha , immunology , disease , confidence interval , health care , economics , economic growth

Although tumor necrosis factor (TNF)-α antagonists are increasingly used in place of nonbiologic comparator medications, their safety profile remains incomplete.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research